Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(7):439; doi:10.1093/jnci/djj149
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Finkelstein, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Finkelstein, J. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

FDA Advisory Panel Voices Persistent Safety Concerns

Joel B. Finkelstein

The first 10% of the full text of this article appears below.

The U.S. Food and Drug Administration has not done enough to improve oversight of the drug approval and surveillance process, according to a panel of safety experts that advises the agency.

At the February meeting of the FDA's Drug Safety and Risk . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?